{"denoms":[{"counts":[{"groupId":"BG000","value":"8"}],"units":"Participants"},{"counts":[{"groupId":"BG000","value":"3"}],"units":"Evaluable Patients"}],"groups":[{"description":"Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.\n\nAntineoplaston therapy (Atengenal + Astugenal): Patients with advanced mesothelioma will receive Antineoplaston therapy (Atengenal + Astugenal).\n\nThe daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.hourly interEach infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.","id":"BG000","title":"Arm: Experimental: Antineoplaston Therapy"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"8.9527","value":"60.0"}]}]}],"denomUnitsSelected":"Participants","dispersionType":"STANDARD_DEVIATION","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Male"}]}],"denomUnitsSelected":"Participants","paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"Eight patients were enrolled in the study, only 3 patient was evaluable.","typeUnitsAnalyzed":"Evaluable Patients"}